Clinical trials: Metastatic Kidney Carcinoma
Kidney Cancer, Renal Cell Carcinoma
Clinical Trial Studying a Personalized Cancer Vaccine in Patients With Non-metastatic Kidney Cancer
This is an international, open label, randomized phase 3 trial in which patients with surgically removable kidney cancer will be randomly selected post-operatively to receive adjuvant treatment with autologous HSPPC-96 or no…
- Trial name
- NCT00126178
- Testing
- HSPPC-96
- Where
- 7 sites in United States, Canada
- Volunteers
- 600 people
- Sponsor
- Agenus Inc.
Liver Cancer (Primary and Metastatic), Renal Cancer
Intra-procedural Spectral CT for Image-guided Embolization and Ablation in Interventional Oncology
This is a pilot study to evaluate the feasibility, image quality, and procedural utility of a novel spectral CT technique using Canon Medical's 4D CT system during image-guided interventional oncology procedures
- Trial name
- NCT07303725
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Palo Alto Veterans Institute for Research
Cervical Cancer, Renal Cancer
T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-DP0401 Positive
Background: The National Cancer Institute (NCI) Surgery Branch has developed an experimental therapy for treating patients with metastatic cancer that involves taking white blood cells from the patient, growing them in the…
- Conditions
- Cervical Cancer, Renal Cancer, Urothelial Cancer, Melanoma
- Trial name
- NCT02111850
- Testing
- Anti-MAGE-A3-DP4 T Cell Receptor (TCR) Peripheral Blood Lymphocytes (PBL), Cyclophosphamide, Fludarabine
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- National Cancer Institute (NCI)
Metastatic Clear Cell Renal Cell Carcinoma
[18F] PSMA-1007 PET/CT in Metastatic Clear Cell Renal Cell Carcinoma
Staging of kidney cancer is primarily achieved by computerized tomography (CT) scans or magnetic resonance imaging (MRI). If a patient is found to have limited metastatic disease, surgical removal or radiation therapy could be…
- Trial name
- NCT06428708
- Testing
- [18F] PSMA-1007 PET/CT
- Where
- Canada
- Volunteers
- 30 people
- Sponsor
- Western University
Melanoma, Renal Cell Carcinoma
A Dose Escalation and Cohort Expansion Study of NKTR-214 in Combination With Nivolumab and Other Anti-Cancer Therapies in Patients With Select Advanced Solid Tumors
In this four-part study, NKTR-214 was administered in combination with nivolumab and with/without other anticancer therapies. Part 1 considered escalating doublet (NKTR 214 + nivolumab) doses to determine the RP2D.
- Conditions
- Melanoma, Renal Cell Carcinoma, Non Small Cell Lung Cancer, Urothelial Carcinoma
- Trial name
- PIVOT-02 (NCT02983045)
- Testing
- Dose Escalation Doublet: Combination of NKTR-214 + nivolumab, Dose Expansion Doublet: Combination of NKTR-214 + nivolumab, Schedule Finding Triplet: Combination of NKTR-214+ nivolumab+ ipilimumab
- Where
- 58 sites in United States, Belgium and 6 more
- Volunteers
- 557 people
- Sponsor
- Nektar Therapeutics
Metastatic Renal Cell Carcinoma
Retrospective Analysis of Patients With Metastatic Renal Cell Carcinoma Treated With CABOzantinib
CABOGEN is a Observational, retrospective, multicenter study that will enroll patients with metastatic clear cell renal carcinoma (mccRCC) treated with cabozantinib after one or more previous lines of treatment that included…
- Trial name
- CABOGEN (NCT06548867)
- Testing
- Cabozantinib
- Where
- Italy
- Volunteers
- 80 people
- Sponsor
- Gruppo Oncologico Italiano di Ricerca Clinica
Solid Tumor, Adult, Metastatic Solid Tumor
Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors
This first-in-human, open-label, multicenter, multi-arm dose-escalation study is designed to evaluate the safety, PK, and PD of ADU-1805, an anti- SIRPα monoclonal antibody, as monotherapy and in combination with pembrolizumab…
- Conditions
- Solid Tumor, Adult, Metastatic Solid Tumor, Refractory Cancer, CRC, Colorectal Cancer
- Trial name
- NCT05856981
- Testing
- ADU-1805, Pembrolizumab
- Where
- 11 sites in United States, Belgium and 1 more
- Volunteers
- 130 people
- Sponsor
- Sairopa B.V.
Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Renal Pelvis and Ureter Urothelial Carcinoma
Enfortumab Vedotin and Pembrolizumab With Cystectomy and/or Ureterectomy for Locally Advanced or Metastatic Bladder and Upper Urothelial Tract Cancer, CAST-AI Trial
This phase IV trial tests the impact of standard of care enfortumab vedotin and pembrolizumab followed by removal of all or part of the bladder (cytoreductive cystectomy) and/or removal of all or part of the tube that carriers…
- Conditions
- Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Renal Pelvis and Ureter Urothelial Carcinoma, Metastatic Bladder Urothelial Carcinoma, Metastatic Renal Pelvis and Ureter Urothelial Carcinoma
- Trial name
- NCT06764095
- Testing
- Biospecimen Collection, Computed Tomography, Cystectomy
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- Mayo Clinic
Anti-p53 TCR-Gene
Phase II Study of Metastatic Cancer That Overexpresses P53 Using Lymphodepleting Conditioning Followed by Infusion of Anti-P53 TCR-Gene Engineered Lymphocytes
Background: The p53 gene normally suppresses tumor growth, but when it is mutated, or damaged, tumors can grow unchecked. In cancers where the p53 gene has mutated, an increased level of p53(overexpression of p53) can be measured…
- Trial name
- NCT00393029
- Testing
- anti-protein 53 or tumor protein 53 (p53) T-cell receptor transduced peripheral blood lymphocytes, aldesleukin, filgrastim
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- National Cancer Institute (NCI)
Renal Cell Carcinoma
A Study of Pazopanib With or Without Abexinostat in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma (RENAVIV)
This is a randomized, Phase 3, double-blind, placebo-controlled study of pazopanib plus abexinostat versus pazopanib plus placebo in patients with locally advanced unresectable or metastatic renal cell carcinoma (RCC).
- Trial name
- NCT03592472
- Testing
- Pazopanib, Abexinostat
- Where
- 38 sites in United States, China and 4 more
- Volunteers
- 413 people
- Sponsor
- Xynomic Pharmaceuticals, Inc.
Non-Small Cell Lung Cancer, Renal Cell Carcinoma
Study of JANX008 in Subjects With Advanced or Metastatic Solid Tumor Malignancies
This study is a first-in-human (FIH), Phase 1/1b, open-label, multicenter dose escalation and dose expansion study to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary anti-tumor…
- Conditions
- Non-Small Cell Lung Cancer, Renal Cell Carcinoma, Squamous Cell Carcinoma of the Head and Neck, Colorectal Carcinoma
- Trial name
- NCT05783622
- Testing
- JANX008
- Where
- 18 sites in United States
- Volunteers
- 130 people
- Sponsor
- Janux Therapeutics
Cancer
MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma
RATIONALE: MS-275 may stop the growth of cancer cells by blocking the enzymes necessary for their growth. PURPOSE: This phase I trial is studying the side effects and best dose of MS-275 in treating patients with advanced solid…
- Trial name
- NCT00020579
- Testing
- entinostat
- Where
- 3 sites in United States
- Volunteers
- 75 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Kidney Cancer, Sarcoma
Combination Chemotherapy and Radiation Therapy in Treating Patients With Peripheral Neuroectodermal Tumors, Ewing's Sarcoma, Wilms' Tumor, or Bone Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug or combining chemotherapy with radiation therapy may kill more tumor cells.
- Trial name
- NCT00002466
- Testing
- cyclophosphamide, doxorubicin hydrochloride, etoposide
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Clear Cell Renal Cell Carcinoma, Stage IV Renal Cell Cancer
Sunitinib Malate in Treating Patients With Previously Untreated Metastatic Kidney Cancer
RATIONALE: Sunitinib malate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth or by blocking blood flow to the tumor.
- Trial name
- NCT01158222
- Testing
- sunitinib malate
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- Case Comprehensive Cancer Center
Metastatic Disease, Renal Cell Carcinoma
Study Comparing Association Between Sorafenib and Interleukin-2 (IL-2) Versus Sorafenib in 1st Line Therapy in Advanced (Adv) Renal Cell Carcinoma (RCC)
The ROSORC trial is a randomized study comparing the efficacy of a new association (sorafenib and IL-2) versus the standard therapy (sorafenib) in patients affected by different histotypes of metastatic RCC.
- Trial name
- ROSORC (NCT00609401)
- Testing
- Nexavar (Sorafenib), IL-2
- Where
- Italy
- Volunteers
- 90 people
- Sponsor
- Italian Trial in Medical Oncology
Refractory Clear Cell Renal Cell Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma
Casdatifan for the Treatment of Refractory Metastatic Clear Cell Renal Cell Carcinoma
This is a single-institution, pilot study of oral casdatifan, a selective HIF-2α inhibitor, in patients with metastatic clear cell renal cell carcinoma refractory to prior IO- and VEGF-based therapies.
- Trial name
- NCT07748988
- Testing
- casdatifan
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Renal Cell Cancer Metastatic, Hypertension
Sunitinib Treatment on Tissue Sodium Accumulation (TSS2)
Here, it is investigated how sunitinib, a tyrosine kinase-inhibitor targeting vascular endothelial growth factor receptors, might influence sodium homeostasis in the skin and if this is related to a well-described treatment…
- Conditions
- Renal Cell Cancer Metastatic, Hypertension, Sodium Imbalance
- Trial name
- NCT04368546
- Testing
- Sunitinib
- Where
- Germany
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Charite University, Berlin, Germany
Metastatic Renal Cell Carcinoma
Phase 2 Study of Panzem® NCD Alone and Combined With Sunitinib Malate in Patients With Metastatic Renal Cell Carcinoma
This open-label, multicenter, Phase 2 trial, will assess the anti tumor activity, safety and pharmacodynamics, of Panzem® NCD with or without Sunitinib Malate in patients with metastatic renal cell carcinoma progressing on…
- Trial name
- NCT00444314
- Testing
- Panzem® NCD, Sunitinib Malate
- Where
- 3 sites in United States
- Volunteers
- 82 people
- Sponsor
- CASI pharmaceuticals, Inc.
Metastatic Renal Cell Carcinoma
A Phase II Study Bolstering Outcomes by Optimizing Immunotherapy Strategies With Evolocumab and Nivolumab in Patients With Metastatic Renal Cell Carcinoma (BOOST-RCC)
To learn if evolocumab and nivolumab can control metastatic and refractory renal cell carcinoma. The safety of this drug combination will also be studied.
- Trial name
- NCT06284564
- Testing
- Evolocumab, Nivolumab
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- M.D. Anderson Cancer Center
Metastatic Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8
Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial
This phase II trial tests whether the addition of radiation to the primary tumor, typically given with stereotactic ablative radiation therapy (SABR), in combination with standard of care immunotherapy improves outcomes in…
- Conditions
- Metastatic Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8, Unresectable Renal Cell Carcinoma
- Trial name
- SAMURAI (NCT05327686)
- Testing
- Avelumab, Axitinib, Biospecimen Collection
- Where
- 348 sites in United States, Australia and 2 more
- Volunteers
- 240 people
- Sponsor
- NRG Oncology
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.